Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Advances in stem cell research over the past few decades have coincided with large increases in haemopoietic stem cell transplantation (HSCT) using either bone marrow, peripheral blood or cord blood-derived stem cells. Alongside this growth has come an increase in the role played by regulatory bodies, both governmental and professional, to ensure that those undertaking such procedures do so in a manner so as to minimize the risk to patients. Interestingly, government legislation encompasses not only cellular therapies, but also the use of tissues and organs, as many of the processes and procurement procedures involved are similar. In this review, we analyse the trends in HSCT, describe the development and impact of legislation within Europe on this practice and outline the vital role played by the UK blood services in providing robust and high-quality HSCT services.

Original publication

DOI

10.1111/j.1423-0410.2007.00974.x

Type

Journal article

Journal

Vox sanguinis

Publication Date

01/2008

Volume

94

Pages

6 - 17

Addresses

Stem Cells and Immunotherapies, National Blood Service - Manchester, National Health Service Blood and Transplant, Manchester, UK. eric.austin@nbs.nhs.uk

Keywords

Humans, Hematopoietic Stem Cell Transplantation, European Union, History, 20th Century, History, 21st Century, Blood Banks, State Medicine, United Kingdom